NOV.DE vs. LYP6.DE

Last updated Jun 13, 2026

NOV.DE (Novo Nordisk A/S) is a stock, while LYP6.DE (Amundi Core STOXX Europe 600 (DR) UCITS ETF Acc) is Europe Equities fund tracking the STOXX® Europe 600. Over the past 10 years, NOV.DE returned 17.16%/yr vs 10.02%/yr for LYP6.DE. At a 0.32 correlation, their price movements are largely independent.

Performance

NOV.DE vs. LYP6.DE - Performance Comparison

The chart below illustrates the hypothetical performance of a €10,000 investment in Novo Nordisk A/S (NOV.DE) and Amundi Core STOXX Europe 600 (DR) UCITS ETF Acc (LYP6.DE). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, NOV.DE achieves a -10.35% return, which is significantly lower than LYP6.DE's 8.98% return. Over the past 10 years, NOV.DE has outperformed LYP6.DE with an annualized return of 17.16%, while LYP6.DE has yielded a comparatively lower 10.02% annualized return.

NOV.DE

• 1D: 0.21%
• 1M: -5.31%
• YTD: -10.35%
• 6M: -8.05%
• 1Y: -43.08%
• 3Y*: 4.29%
• 5Y*: 20.26%
• 10Y*: 17.16%

LYP6.DE

• 1D: 1.90%
• 1M: 4.01%
• YTD: 8.98%
• 6M: 11.60%
• 1Y: 18.44%
• 3Y*: 14.24%
• 5Y*: 9.81%
• 10Y*: 10.02%

*Multi-year figures are annualized to reflect compound growth (CAGR)

NOV.DE vs. LYP6.DE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
NOV.DE Novo Nordisk A/S	-10.35%	-45.88%	-9.45%	201.62%	32.53%	76.94%	16.00%	38.98%	-7.34%	39.52%
LYP6.DE Amundi Core STOXX Europe 600 (DR) UCITS ETF Acc	8.98%	20.82%	8.25%	15.97%	-10.40%	24.81%	-1.72%	28.59%	-11.28%	11.31%

Correlation

The correlation between NOV.DE and LYP6.DE is 0.31, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.31
Correlation (3Y) Calculated over the trailing 3-year period	0.27
Correlation (5Y) Calculated over the trailing 5-year period	0.27
Correlation (10Y) Calculated over the trailing 10-year period	0.29
Correlation (All Time) Calculated using the full available price history since Apr 3, 2013	0.32

Return for Risk

NOV.DE vs. LYP6.DE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NOV.DE

NOV.DE Risk / Return Rank: 12
NOV.DE Sharpe Ratio Rank: 9
NOV.DE Sortino Ratio Rank: 11
NOV.DE Omega Ratio Rank: 10
NOV.DE Calmar Ratio Rank: 12
NOV.DE Martin Ratio Rank: 17

LYP6.DE

LYP6.DE Risk / Return Rank: 47
LYP6.DE Sharpe Ratio Rank: 45
LYP6.DE Sortino Ratio Rank: 47
LYP6.DE Omega Ratio Rank: 47
LYP6.DE Calmar Ratio Rank: 45
LYP6.DE Martin Ratio Rank: 50

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NOV.DE vs. LYP6.DE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Novo Nordisk A/S (NOV.DE) and Amundi Core STOXX Europe 600 (DR) UCITS ETF Acc (LYP6.DE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	NOV.DE	LYP6.DE	Difference
Sharpe ratio: Return per unit of total volatility	-0.85	1.41	-2.26
Sortino ratio: Return per unit of downside risk	-1.07	2.06	-3.13
Omega ratio: Gain probability vs. loss probability	0.85	1.26	-0.42
Calmar ratio: Return relative to maximum drawdown	-0.80	1.94	-2.74
Martin ratio: Return relative to average drawdown	-1.16	7.50	-8.65

NOV.DE vs. LYP6.DE - Sharpe Ratio Comparison

The current NOV.DE Sharpe Ratio is -0.85, which is lower than the LYP6.DE Sharpe Ratio of 1.41. The chart below compares the historical Sharpe Ratios of NOV.DE and LYP6.DE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

NOV.DE vs. LYP6.DE - Drawdown Comparison

The maximum NOV.DE drawdown since its inception was -76.24%, which is greater than LYP6.DE's maximum drawdown of -35.51%. Use the drawdown chart below to compare losses from any high point for NOV.DE and LYP6.DE.

Drawdown Indicators

	NOV.DE	LYP6.DE	Difference
Max Drawdown Largest peak-to-trough decline	-76.24%	-35.51%	-40.73%
Max Drawdown (1Y) Largest decline over 1 year	-53.78%	-9.45%	-44.33%
Max Drawdown (3Y) Largest decline over 3 years	-76.24%	-16.26%	-59.98%
Max Drawdown (5Y) Largest decline over 5 years	-76.24%	-20.71%	-55.53%
Max Drawdown (10Y) Largest decline over 10 years	-76.24%	-35.51%	-40.73%
Current Drawdown Current decline from peak	-70.33%	-0.24%	-70.09%
Average Drawdown Average peak-to-trough decline	-11.57%	-5.23%	-6.34%
Ulcer Index Depth and duration of drawdowns from previous peaks	35.53%	2.45%	+33.08%

Volatility

NOV.DE vs. LYP6.DE - Volatility Comparison

Novo Nordisk A/S (NOV.DE) has a higher volatility of 9.39% compared to Amundi Core STOXX Europe 600 (DR) UCITS ETF Acc (LYP6.DE) at 4.31%. This indicates that NOV.DE's price experiences larger fluctuations and is considered to be riskier than LYP6.DE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NOV.DE	LYP6.DE	Difference
Volatility (1M) Calculated over the trailing 1-month period	9.39%	4.31%	+5.08%
Volatility (6M) Calculated over the trailing 6-month period	37.99%	10.85%	+27.14%
Volatility (1Y) Calculated over the trailing 1-year period	50.46%	13.06%	+37.40%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	57.30%	14.43%	+42.87%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	44.50%	15.56%	+28.94%

Dividends

NOV.DE vs. LYP6.DE - Dividend Comparison

NOV.DE's dividend yield for the trailing twelve months is around 4.10%, while LYP6.DE has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
LYP6.DE Amundi Core STOXX Europe 600 (DR) UCITS ETF Acc	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NOV.DE Novo Nordisk A/S	4.10%	3.54%	1.59%	1.02%	2.36%	2.54%	3.97%	4.18%	5.34%	4.55%	7.38%	2.50%

Frequently Asked Questions

Can I hold both NOV.DE and LYP6.DE in my portfolio?

NOV.DE and LYP6.DE have a correlation of 0.31, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.